Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 187-189

  Theoharides, Theoharis C ^a   Conti, Pio ^b   Economu, Marina ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCRINE DISRUPTOR; FLAVONOID; LUTEOLIN; QUERCETIN;

DRUG ACTIVITY; DRUG EFFECT; ENCEPHALITIS; HORMONE ACTION; HUMAN; IMMUNOMODULATION; NEUROPSYCHIATRY; NONHUMAN; NOTE; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; BRAIN; HUMANS; INFLAMMATION; LUTEOLIN; MENTAL DISORDERS; QUERCETIN;

EID: 84896393412     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000084     Document Type: Note

References (58)

1. Theoharides TC, Weinkauf C, Conti P. Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol. 2004;24: 577-581.
2. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9: 46-56.
3. Almond M. Depression and inflammation: examining the link. Current Psychiatry. 2013;12: 24-32.
4. Stertz L, Magalhães PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry. 2013;26: 19-26.
5. Verri M, Pastoris O, Dossena M, et al. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. Int J Immunopathol Pharmacol. 2012;25: 345-353.
6. El-Ansary A, Al-Ayadhi L. Neuroinflammation in autism spectrum disorders. J Neuroinflammation. 2012;9: 265.
7. Theoharides TC, Asadi S, Patel AB. Focal brain inflammation and autism. J Neuroinflammation. 2013;10: 46.
8. Theoharides TC, Zhang B, Conti P. Decreased mitochondrial function and increased brain inflammation in bipolar disorder and other neuropsychiatric diseases. J Clin Psychopharmacol. 2011;31: 685-687.
9. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17: 290-314.
10. Theoharides TC, Asadi S, Panagiotidou S, et al. The "missing link" in autoimmunity and autism: extracellular mitochondrial components secreted from activated live mast cells. Autoimmun Rev. 2013;12: 1136-1142.
11. Sommer IE, de Witte L, Begemann M, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73: 414-419.
12. Theoharides TC, Asadi S, Weng Z, et al. Serotonin-selective reuptake inhibitors and nonsteroidal anti-inflammatory drugsVimportant considerations of adverse interactions especially for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome. J Clin Psychopharmacol. 2011;31: 403-405.
13. Joëls M, Sarabdjitsingh RA, Karst H. Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol Rev. 2012;64: 901-938.
14. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52: 673-751.
15. Grosso C, Valentão P, Ferreres F, et al. The use of flavonoids in central nervous system disorders. Curr Med Chem. 2013;20: 4694-4719.
16. Beking K, Vieira A. Flavonoid intake and disability-adjusted life years due to Alzheimer's and related dementias: a population-based study involving twenty-three developed countries. Public Health Nutr. 2010;13: 1403-1409.
17. Gomez-Pinilla F, Nguyen TT. Natural mood foods: the actions of polyphenols against psychiatric and cognitive disorders. Nutr Neurosci. 2012;15: 127-133.
18. Sampson L, Rimm E, Hollman PC, et al. Flavonol and flavone intakes in US health professionals. J Am Diet Assoc. 2002;102: 1414-1420.
19. Goulas V, Papoti VT, Exarchou V, et al. Contribution of flavonoids to the overall radical scavenging activity of olive (Olea europaea L.) leaf polar extracts. J Agric Food Chem. 2010;58: 3303-3308.
20. Blekas G, Vassilakis C, Harizanis C, et al. Biophenols in table olives. J Agric Food Chem. 2002;50: 3688-3692.
21. Somerset SM, Johannot L. Dietary flavonoid sources in Australian adults. Nutr Cancer. 2008;60: 442-449.
22. Exarchou V, Nenadis N, Tsimidou M, et al. Antioxidant activities and phenolic composition of extracts from Greek oregano, Greek sage, and summer savory. J Agric Food Chem. 2002;50: 5294-5299.
23. Harwood M, Danielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007;45: 2179-2205.
24. Kawanishi S, Oikawa S, Murata M. Evaluation for safety of antioxidant chemopreventive agents. Antioxid Redox Signal. 2005;7: 1728-1739.
25. Williams K, Wheeler DM, Silove N, et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010;8: CD004677.
26. Dove D, Warren Z, McPheeters ML, et al. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics. 2012;130: 717-726.
27. Rezai-Zadeh K, Douglas Shytle R, Bai Y, et al. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J Cell Mol Med. 2009;13: 574-588.
28. Taliou A, Zintzaras E, Lykouras L, et al. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther. 2013;35: 592-602.
29. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A. 2008;105: 7534-7539.
30. Dirscherl K, Karlstetter M, Ebert S, et al. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation. 2010;7: 3.
31. Kimata M, Shichijo M, Miura T, et al. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy. 2000;30: 501-508.
32. Kempuraj D, Madhappan B, Christodoulou S, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol. 2005;145: 934-944.
33. Chen HQ, Jin ZY, Wang XJ, et al. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett. 2008;448: 175-179.
34. Jang SW, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A. 2010;107: 2687-2692.
35. Zhu LH, Bi W, Qi RB, et al. Luteolin inhibits microglial inflammation and improves neuron survival against inflammation. Int J Neurosci. 2011;121: 329-336.
36. Asadi S, Zhang B, Weng Z, et al. Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. Int J Immunopathol Pharmacol. 2010;23: 1015-1020.
37. Verbeek R, Plomp AC, van Tol EA, et al. The flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cells. Biochem Pharmacol. 2004;68: 621-629.
38. Kempuraj D, Tagen M, Iliopoulou BP, et al. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. Br J Pharmacol. 2008;155: 1076-1084.
39. Parker-Athill E, Luo D, Bailey A, et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol. 2009;217: 20-27.
40. Jang S, Dilger RN, Johnson RW. Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J Nutr. 2010;140: 1892-1898.
41. Liu Y, Tian X, Gou L, et al. Luteolin attenuates diabetes-associated cognitive decline in rats. Brain Res Bull. 2013;94: 23-29.
42. Nordeen SK, Bona BJ, Jones DN, et al. Endocrine disrupting activities of the flavonoid nutraceuticals luteolin and quercetin. Horm Cancer. 2013;4: 293-300.
43. Lu DF, Yang LJ, Wang F, et al. Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19). J Agric Food Chem. 2012. [Epub ahead of print].
44. Scippo ML, Argiris C, Van De Weerdt C, et al. Recombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors. Anal Bioanal Chem. 2004;378: 664-669.
45. Guo W, Kong E, Meydani M. Dietary polyphenols, inflammation, and cancer. Nutr Cancer. 2009;61: 807-810.
46. Lin Y, Shi R, Wang X, et al. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8: 634-646.
47. Lin YS, Tsai PH, Kandaswami CC, et al. Effects of dietary flavonoids, luteolin, and quercetin on the reversal of epithelial-mesenchymal transition in A431 epidermal cancer cells. Cancer Sci. 2011;102: 1829-1839.
48. Horváthová K, Chalupa I, Sebová L, et al. Protective effect of quercetin and luteolin in human melanoma HMB-2 cells. Mutat Res. 2005;565: 105-112.
49. Lee LT, Huang YT, Hwang JJ, et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 2002;22: 1615-1627.
50. Amin AR, Wang D, Zhang H, et al. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem. 2010;285: 34557-34565.
51. Jeon YW, Suh YJ. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncol Rep. 2013;29: 819-825.
52. Shimoi K, Okada H, Furugori M, et al. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett. 1998;438: 220-224.
53. López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009;9: 31-59.
54. Theoharides TC, Konstantinidou A. Antidepressants and risk of cancer: a case of misguided associations and priorities. J Clin Psychopharmacol. 2003;13: 1-4.
55. Bolling BW, Court MH, Blumberg JB, et al. The kinetic basis for age-associated changes in quercetin and genistein glucuronidation by rat liver microsomes. J Nutr Biochem. 2010;21: 498-503.
56. Theoharides TC, Asadi S. Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders. J Clin Psychopharmacol. 2012;32: 437-440.
57. Scahill L, Lord C. Subject selection and characterization in clinical trials in children with autism. CNS Spectr. 2004;9: 22-32.
58. Schmidt BM, Ribnicky DM, Lipsky PE, et al. Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol. 2007;3: 360-366.